• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

IJERPH, Vol. 18, Pages 8995: COVID-19 Screening by Anti-SARS-CoV-2 Antibody Seropositivity: Clinical and Epidemiological Characteristics, Comorbidities, and Food Intake Quality
In conclusion, this study supports the association of diabetes as a principal risk factor for SARS-CoV-2 infection in the Mexican population. The results do not support previous associations between blood group or influenza vaccination as protective factors against SARS-CoV-2 infection. However, frequent consumption of polyunsaturated fats is highlighted as a new possible associated factor with COVID-19, which more studies should corroborate as with all novel findings.
Source: International Journal of Environmental Research and Public Health - August 26, 2021 Category: Environmental Health Authors: Gabriela Macedo-Ojeda Jos é Francisco Muñoz-Valle Patricia Yokogawa-Teraoka Andrea Carolina Machado-Sulbar án Mar ía Guadalupe Loza-Rojas Atziri Citlally Garc ía-Arredondo Rafael Tejeda-Constantini Alejandra Natali Vega-Maga ña Guillermo Gonz ález- Tags: Article Source Type: research

Fight Aging! Newsletter, June 14th 2021
In conclusion, a number of high-income countries, changes in health expectancies over time have not kept pace with the growth in life expectancy. That is, people are living longer but disability and poor health are occupying an increasing proportion of later life. Our findings suggest that countries still need to make significant progress to achieve the WHO's Decade of Healthy Ageing goal of healthier, longer lives for all. Progress on Understanding Why Human Growth Hormone Receptor Variants are Associated with Greater Longevity https://www.fightaging.org/archives/2021/06/progress-on-understanding-why-human-gro...
Source: Fight Aging! - June 13, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

2019 Health Law Professors Conference
Conclusion
Source: blog.bioethics.net - March 27, 2019 Category: Medical Ethics Authors: Thaddeus Mason Pope, JD, PhD Tags: Health Care syndicated Source Type: blogs